vs
Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $43.5M, roughly 1.1× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs -47.3%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs -20.2%).
Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
DX vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.5M | $47.7M |
| Net Profit | — | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | — | 14.3% |
| Net Margin | — | -4.8% |
| Revenue YoY | 531.3% | -47.3% |
| Net Profit YoY | — | -200.9% |
| EPS (diluted) | $1.59 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $43.5M | $47.7M | ||
| Q3 25 | $30.6M | $122.1M | ||
| Q2 25 | $23.1M | $85.2M | ||
| Q1 25 | $17.1M | $41.1M | ||
| Q4 24 | — | $90.5M | ||
| Q3 24 | — | $91.6M | ||
| Q2 24 | — | $94.4M | ||
| Q1 24 | $-3.2M | $74.9M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | $150.4M | $40.1M | ||
| Q2 25 | $-13.6M | $23.6M | ||
| Q1 25 | $-3.1M | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $3.6M | ||
| Q2 24 | — | $-860.0K | ||
| Q1 24 | $40.1M | $-4.2M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 61.8% | ||
| Q2 25 | — | 53.2% | ||
| Q1 25 | — | -70.7% | ||
| Q4 24 | — | 34.8% | ||
| Q3 24 | — | 28.0% | ||
| Q2 24 | — | 26.5% | ||
| Q1 24 | — | 14.7% |
| Q4 25 | — | -4.8% | ||
| Q3 25 | 491.3% | 32.8% | ||
| Q2 25 | -58.8% | 27.7% | ||
| Q1 25 | -18.0% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | -0.9% | ||
| Q1 24 | -1256.8% | -5.6% |
| Q4 25 | $1.59 | $0.01 | ||
| Q3 25 | $1.08 | $0.23 | ||
| Q2 25 | $-0.14 | $0.14 | ||
| Q1 25 | $-0.06 | $-0.23 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | $0.64 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $531.0M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.5B | $-261.8M |
| Total Assets | $17.3B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.0M | $215.5M | ||
| Q3 25 | $491.0M | $140.4M | ||
| Q2 25 | $387.5M | $92.9M | ||
| Q1 25 | $327.4M | $108.5M | ||
| Q4 24 | — | $88.6M | ||
| Q3 24 | — | $88.2M | ||
| Q2 24 | — | $105.5M | ||
| Q1 24 | $295.7M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $2.5B | $-261.8M | ||
| Q3 25 | $2.0B | $-264.2M | ||
| Q2 25 | $1.6B | $-308.2M | ||
| Q1 25 | $1.4B | $-334.1M | ||
| Q4 24 | — | $-301.3M | ||
| Q3 24 | — | $-311.3M | ||
| Q2 24 | — | $-321.7M | ||
| Q1 24 | $958.5M | $-330.5M |
| Q4 25 | $17.3B | $396.9M | ||
| Q3 25 | $14.2B | $396.1M | ||
| Q2 25 | $11.3B | $342.9M | ||
| Q1 25 | $9.0B | $327.2M | ||
| Q4 24 | — | $350.9M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $395.6M | ||
| Q1 24 | $6.3B | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.8M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.8M | $74.6M | ||
| Q3 25 | $68.3M | $47.6M | ||
| Q2 25 | $31.9M | $-15.1M | ||
| Q1 25 | $6.4M | $20.0M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.5M | ||
| Q1 24 | $-17.1M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 0.45× | 1.19× | ||
| Q2 25 | — | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
